TMX Newsfile Pharmaceuticals News Releases

Hemostemix Grants Stock Options

Wed, 22 Jul 2026 16:50:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue

Wed, 22 Jul 2026 06:30:00 -0400

Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based specialty pharmacy specializing in the management of complex therapies for chronic disease states.Evergreen generated Revenue of approximately US$78.8 million with Normalized EBITDA (1) of US$0.60 million, for the twelve-month period ended December 31, 2025. Evergreen is a profitable company on both EBITDA and Net Income basis and would be immediately...

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experiencePursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundationKetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchiseToronto, Ontario--(Newsfile Corp. - July 21, 2026) -...

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Tue, 21 Jul 2026 07:00:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory...

Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld

Tue, 21 Jul 2026 00:40:00 -0400

Ad hoc announcement pursuant to Art. 53 LR The next phase of the greenfield project in Sisslerfeld (Eiken, Switzerland) will be implemented as part of a strategic collaboration. Total investment amounts to more than CHF 500 million. Start of commercial production at the new site is expected in 2030. Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the signing of an agreement to supply large volumes...

Richards Group Inc. Announces July 2026 Dividend

Mon, 20 Jul 2026 15:54:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended July 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on July 31, 2026 and will be payable on August 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends...

CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research

Mon, 20 Jul 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science.CBIH's invention centers on an intranasal medicine...

Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker

Fri, 17 Jul 2026 17:30:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization and liquidity services to the...